Inhibitory control of angiotensin-converting enzyme by ramipril in migraine
- Author:
Hyun-Jung Park
;
Soon-Tae Lee
;
Manho Kim
- Publication Type:Journal Article
- From:Neurology Asia
2013;18(3):289-291
- CountryMalaysia
- Language:English
-
Abstract:
Background: Renin-angiotensin systems (RAS) are involved in the physiology of migraine. Ramipril
is an angiotensin-converting enzyme inhibitor. We tested whether ramipril has an effect on migraine.
Methods: The study was designed as a prospective open-labeled trial in a single center. All patients
were asked to maintain a headache diary. Ramipril was administered at 5mg/day (2.5mg twice a day)
and subjects were checked every 4 weeks up to 12 weeks. Results: The mean number of headache
days was 19.9 ± 11.2 days per month at baseline, and 12.0 ± 11.5 at 12 weeks (p<0.001 vs. baseline)
with a responder rate of 41.9%. Stratified analysis by migraine frequency (15 days a month > vs. <15
days a month) did not show a difference. Mean blood pressure was not altered.
Conclusions: Ramipril prevented migraine attacks independently from blood pressure. This result
supports a link between renin-angiotensin system and migraine pathophysiology (Clinicaltrials.gov
identifier: NCT01402479).
- Full text:P020150706558619072282.pdf
